140 related articles for article (PubMed ID: 28225679)
1. Pediatric Drug Formulations - Unintended Consequences of Legislation.
Probst LA; Welch TR
N Engl J Med; 2017 Feb; 376(8):795-796. PubMed ID: 28225679
[No Abstract] [Full Text] [Related]
2. Europe consults on more accurate prescribing for children.
Rogers A
Lancet; 2002 Mar; 359(9309):862. PubMed ID: 11897300
[No Abstract] [Full Text] [Related]
3. Pediatric formulations: international issues and potential solutions.
Knoppert DC
Paediatr Drugs; 2009; 11(1):55-6. PubMed ID: 19127956
[TBL] [Abstract][Full Text] [Related]
4. Medicines pricing singled out.
Buchanan E
S Afr Med J; 2004 May; 94(5):334. PubMed ID: 15211941
[No Abstract] [Full Text] [Related]
5. NerveCenter: Unintended effects of biologic drug market protection.
Stone K
Ann Neurol; 2010 Nov; 68(5):A11-2. PubMed ID: 21031566
[TBL] [Abstract][Full Text] [Related]
6. The Price of Precision: Genetic Testing and Drug Costs in America.
Rich K; Terry SF
Genet Test Mol Biomarkers; 2018 Jul; 22(7):403-404. PubMed ID: 30020834
[No Abstract] [Full Text] [Related]
7. [Drugs for children--when temporary solutions become routine].
Kalikstad B; Westergren T
Tidsskr Nor Laegeforen; 2006 Mar; 126(7):930-2. PubMed ID: 16554887
[No Abstract] [Full Text] [Related]
8. How do Japanese children take their medicines, and what are pharmacists and paediatricians doing about it?
Nakamura H; Ishikawa Y
Int J Pharm; 2014 Aug; 469(2):249-50. PubMed ID: 24704105
[TBL] [Abstract][Full Text] [Related]
9. Time to change the paradigm of children's medicines from liquid formulations to flexible solid oral dosage forms.
Hoppu K
Ceylon Med J; 2016 Sept; 61(3):93-95. PubMed ID: 27727406
[No Abstract] [Full Text] [Related]
10. Eunice Kennedy Shriver National Institute of Child Health and Human Development Pediatrics Formulation Initiative: proceedings from the Second Workshop on Pediatric Formulations.
Giacoia GP; Taylor-Zapata P; Zajicek A
Clin Ther; 2012 Nov; 34(11):S1-10. PubMed ID: 23149008
[TBL] [Abstract][Full Text] [Related]
11. [Development costs, regulation and audit in the German SHI Drug Sector].
Kamp F; Walter P; Bücheler R
Gesundheitswesen; 2014 Jan; 76(1):7-18. PubMed ID: 24446140
[No Abstract] [Full Text] [Related]
12. The use of unlicensed and off-label medicines in the neonate.
Conroy S; McIntyre J
Semin Fetal Neonatal Med; 2005 Apr; 10(2):115-22. PubMed ID: 15701577
[TBL] [Abstract][Full Text] [Related]
13. [Reference prices].
Rey Abella ME
Aten Primaria; 1999 Sep; 24(5):252-4. PubMed ID: 10590555
[No Abstract] [Full Text] [Related]
14. Enforcement of the current good manufacturing practices for solid oral dosage forms after United States v. Barr Laboratories.
Jimenez FA
Food Drug Law J; 1997; 52(1):67-82. PubMed ID: 10346711
[No Abstract] [Full Text] [Related]
15. Pharmaceuticals and medical devices: cost savings.
Steiner DJ
Issue Brief Health Policy Track Serv; 2013 Dec; ():1-32. PubMed ID: 24482891
[No Abstract] [Full Text] [Related]
16. Drug shortage crisis resolution.
Duffy E
J Pharm Pract; 2012 Dec; 25(6):619-20. PubMed ID: 23222856
[No Abstract] [Full Text] [Related]
17. Laws promote pediatric drug development.
Kuehn BM
JAMA; 2006 Jul; 296(3):271. PubMed ID: 16849655
[No Abstract] [Full Text] [Related]
18. Pediatric drug formulations: challenges and potential solutions.
Nahata MC
Ann Pharmacother; 1999 Feb; 33(2):247-9. PubMed ID: 10084423
[TBL] [Abstract][Full Text] [Related]
19. Pediatric drug development: formulation considerations.
Ali AA; Charoo NA; Abdallah DB
Drug Dev Ind Pharm; 2014 Oct; 40(10):1283-99. PubMed ID: 24483293
[TBL] [Abstract][Full Text] [Related]
20. Basics of compounding foam dosage forms.
Allen LV
Int J Pharm Compd; 2013; 17(4):312-22. PubMed ID: 24261147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
